Abivax Raises $920M on Wall Street and Secures Funding Until 2029
French biotech company Abivax has announced the completion of its public offering of American Depositary Shares (ADS) in the United States, raising a gross amount of $920M following the full exercise of the over-allotment option.
A $920 Million Fundraising
Abivax has finalized its public offering of 7.36 million American Depositary Shares, each representing one ordinary share of the company. The total gross proceeds amounted to approximately $920M (€807.4M), following the full exercise of the over-allotment option by the bookrunners. The estimated net proceeds, after deducting underwriting commissions and fees, are about $874.1M (€767.1M).
Funding Secured Until the Fourth Quarter of 2029
The company estimates that the net proceeds from the offering, combined with its current cash and cash equivalents, will enable it to fund its operations until the fourth quarter of 2029. All ADS were issued by Abivax. Abivax's ordinary shares continue to be traded on Euronext Paris under the symbol 'ABVX', while its ADS are listed on the Nasdaq Global Market under the same symbol.
Syndication and Regulatory Process
Leerink Partners, Morgan Stanley, Piper Sandler, and Guggenheim Securities acted as joint bookrunners. LifeSci Capital served as passive bookrunner. Van Lanschot Kempen served as lead manager. According to Leerink Partners, as the stabilizing agent, no stabilization transactions were carried out and the stabilization period is now closed. An F-3 form was filed with the SEC on July 23, 2025, became effective upon filing, and was amended on June 30, 2026.
